TIAA CREF Investment Management LLC lessened its stake in TESARO, Inc. (NASDAQ:TSRO) by 7.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 341,608 shares of the biopharmaceutical company’s stock after selling 25,911 shares during the period. TIAA CREF Investment Management LLC owned about 0.63% of TESARO worth $47,777,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the business. Teacher Retirement System of Texas boosted its position in TESARO by 2.1% in the 1st quarter. Teacher Retirement System of Texas now owns 2,945 shares of the biopharmaceutical company’s stock worth $453,000 after purchasing an additional 60 shares in the last quarter. Profund Advisors LLC boosted its position in TESARO by 3.8% in the 1st quarter. Profund Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock worth $394,000 after purchasing an additional 93 shares in the last quarter. Stephens Inc. AR boosted its position in TESARO by 6.5% in the 2nd quarter. Stephens Inc. AR now owns 1,874 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 115 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its position in TESARO by 0.9% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 16,740 shares of the biopharmaceutical company’s stock worth $2,576,000 after purchasing an additional 150 shares in the last quarter. Finally, Aperio Group LLC boosted its position in TESARO by 4.5% in the 2nd quarter. Aperio Group LLC now owns 3,658 shares of the biopharmaceutical company’s stock worth $512,000 after purchasing an additional 156 shares in the last quarter.

TESARO, Inc. (TSRO) opened at 118.74 on Wednesday. The company has a 50-day moving average price of $121.03 and a 200 day moving average price of $138.94. TESARO, Inc. has a 1-year low of $96.52 and a 1-year high of $192.94. The firm’s market capitalization is $6.43 billion.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.52) by ($0.30). TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The business had revenue of $29.50 million during the quarter, compared to analysts’ expectations of $18.61 million. During the same quarter last year, the firm earned ($1.28) earnings per share. The firm’s quarterly revenue was down 17.6% compared to the same quarter last year. Analysts expect that TESARO, Inc. will post ($8.67) earnings per share for the current fiscal year.

In other TESARO news, VP Edward C. English sold 10,862 shares of the business’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the sale, the vice president now directly owns 6,258 shares in the company, valued at $844,329.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Grant C. Bogle sold 14,167 shares of the business’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $135.00, for a total value of $1,912,545.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,100 shares of company stock worth $3,387,465. Company insiders own 34.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: “TIAA CREF Investment Management LLC Sells 25,911 Shares of TESARO, Inc. (TSRO)” was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://www.watchlistnews.com/tiaa-cref-investment-management-llc-sells-25911-shares-of-tesaro-inc-tsro/1575535.html.

TSRO has been the topic of several recent research reports. Cann restated a “buy” rating and issued a $199.00 price objective on shares of TESARO in a research report on Monday, June 5th. Credit Suisse Group set a $198.00 price objective on TESARO and gave the stock a “buy” rating in a research report on Monday, June 5th. Oppenheimer Holdings, Inc. set a $199.00 price objective on TESARO and gave the stock a “buy” rating in a research report on Sunday, June 4th. Bank of America Corporation restated a “buy” rating and issued a $154.00 price objective on shares of TESARO in a research report on Tuesday, June 20th. Finally, Gabelli initiated coverage on TESARO in a research report on Friday, July 7th. They issued a “buy” rating and a $175.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $171.42.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO, Inc. (NASDAQ:TSRO).

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.